Literature DB >> 16616051

Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro.

Lei Chen1, Bela Kis, Hirofumi Hashimoto, David W Busija, Yoshio Takei, Hiroshi Yamashita, Yoichi Ueta.   

Abstract

Adrenomedullin 2 (AM2, intermedin) is a recently identified new member of the calcitonin gene-related peptide family. We examined whether AM2 can attenuate the increased blood-brain barrier permeability and cerebral endothelial cell (CEC) death induced by oxidative stress in vitro. Hydrogen peroxide (H(2)O(2), 0.5 mM) induced a continuous decrease of the transendothelial electrical resistance (TEER) and resulted in intercellular gap formations in rat CECs co-cultured with astrocytes. AM2 induced cAMP and nitric oxide production, increased TEER, enhanced peripheral localization of F-actin bands, and attenuated the increased permeability induced by H(2)O(2). AM2 treatment preserved mitochondrial membrane potential and improved CEC viability in H(2)O(2) treated cultures. These effects of AM2 were similar to those what were reported for adrenomedullin. These results suggest that AM2 protects CECs against oxidative injury in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616051     DOI: 10.1016/j.brainres.2006.02.128

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

Review 1.  Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases.

Authors:  Song-Yang Zhang; Ming-Jiang Xu; Xian Wang
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

2.  Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers.

Authors:  M Aslam; U Pfeil; D Gündüz; A Rafiq; W Kummer; H M Piper; T Noll
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 3.  Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.

Authors:  Kazuhiro Takahashi; Ryo Morimoto; Takuo Hirose; Fumitoshi Satoh; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2010-07-02       Impact factor: 3.444

4.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

5.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

6.  Cilostazol strengthens barrier integrity in brain endothelial cells.

Authors:  Shoji Horai; Shinsuke Nakagawa; Kunihiko Tanaka; Yoichi Morofuji; Pierre-Oliver Couraud; Maria A Deli; Masaki Ozawa; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.046

7.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 8.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

9.  Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability.

Authors:  Uwe Pfeil; Muhammad Aslam; Renate Paddenberg; Karin Quanz; Chia L Chang; Jae-Il Park; Barbara Gries; Amir Rafiq; Petra Faulhammer; Anna Goldenberg; Tamara Papadakis; Thomas Noll; Sheau Y T Hsu; Norbert Weissmann; Wolfgang Kummer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-14       Impact factor: 5.464

10.  Intermedin attenuates LPS-induced inflammation in the rat testis.

Authors:  Lei Li; Ping Ma; Yongjun Liu; Chen Huang; Wai-sum O; Fai Tang; Jian V Zhang
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.